Expert Review of Gastroenterology & Hepatology最新文献

Implications of the microbiome after pancreatic cancer resection with regards to morbidity & mortality. 胰腺癌切除术后微生物组对发病率和死亡率的影响。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-11-22 DOI: 10.1080/17474124.2024.2427648

Nabeel Merali, Tarak Chouari, Su Junjun, Timothy A Rockall, Elisa Giovannetti, Nicola Annels, Adam E Frampton

引用次数: 0

Cellular senescence and its pathogenic and therapeutic implications in autoimmune hepatitis. 细胞衰老及其对自身免疫性肝炎的致病和治疗意义。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-11-22 DOI: 10.1080/17474124.2024.2432480

Albert J Czaja

{"title":"Cellular senescence and its pathogenic and therapeutic implications in autoimmune hepatitis.","authors":"Albert J Czaja","doi":"10.1080/17474124.2024.2432480","DOIUrl":"https://doi.org/10.1080/17474124.2024.2432480","url":null,"abstract":"Introduction: Senescent cells are characterized by replicative arrest and phenotypes that produce diverse pro-inflammatory and pro-oxidant mediators. The senescence of diverse hepatic cell types could constitute an unrecognized pathogenic mechanism and prognostic determinant in autoimmune hepatitis. The impact of cellular senescence in autoimmune hepatitis is unknown, and it may suggest adjunctive management strategies.Areas covered: This review describes the molecular mechanisms of cellular senescence, indicates its diagnostic features, suggests its consequences, presents possible therapeutic interventions, and encourages investigations of its pathogenic role and management in autoimmune hepatitis. Treatment prospects include elimination or reversal of senescent cells, generation of ectopic telomerase, reactivation of dormant telomerase, neutralization of specific pro-inflammatory secretory products, and mitigation of the effects of mitochondrial dysfunction.Expert opinion: The occurrence, nature, and consequences of cellular senescence in autoimmune hepatitis must be determined. The senescence of diverse hepatic cell types could affect the outcome of autoimmune hepatitis by impairing hepatic regeneration, intensifying liver inflammation, and worsening hepatic fibrosis. Cellular senescence could contribute to suboptimal responses during conventional glucocorticoid-based therapy. Interventions that target specific pro-inflammatory products of the senescent phenotype or selectively promote apoptosis of senescent cells may be preferred adjunctive treatments for autoimmune hepatitis depending on the cancer risk.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosing and managing gastroparesis - where are we now? 胃痉挛的诊断和管理--我们现在在哪里？

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-11-18 DOI: 10.1080/17474124.2024.2431248

Caroline G Olson, Brian E Lacy

引用次数: 0

Intermediate hepatocellular carcinoma: new horizons and prospects for our patients. 中期肝细胞癌：我们患者的新视野和新前景。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-10-01 Epub Date: 2024-11-01 DOI: 10.1080/17474124.2024.2422367

Federica Lo Prinzi, Federico Rossari, Marianna Silletta, Silvia Foti, Silvia Camera, Francesco Vitiello, Elisabeth Amadeo, Francesco De Cobelli, Luca Aldrighetti, Margherita Rimini, Andrea Casadei-Gardini

{"title":"Intermediate hepatocellular carcinoma: new horizons and prospects for our patients.","authors":"Federica Lo Prinzi, Federico Rossari, Marianna Silletta, Silvia Foti, Silvia Camera, Francesco Vitiello, Elisabeth Amadeo, Francesco De Cobelli, Luca Aldrighetti, Margherita Rimini, Andrea Casadei-Gardini","doi":"10.1080/17474124.2024.2422367","DOIUrl":"10.1080/17474124.2024.2422367","url":null,"abstract":"Introduction: In recent years, significant progress has been made in treatment strategies for intermediate-stage hepatocellular carcinoma (HCC), which is a highly heterogeneous patient population requiring tailored therapies based on tumor characteristics.Methods: We conducted a comprehensive review of treatment approaches for intermediate-stage HCC, highlighting the evolution of treatment options over time. While chemoembolization remains the standard therapy for many patients, it has advanced to include combinations with systemic therapies, known as combination therapy, which is becoming the new standard of care for this group.Conclusion: Based on our clinical and research experience, combination therapy is increasingly recognized as the preferred first-line treatment for intermediate-stage HCC patients. This approach allows most patients to be candidates for subsequent curative-intent treatments, while a smaller number will require palliative care.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"661-672"},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma. 在肝细胞癌早期阶段提供辅助治疗和新辅助治疗。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-10-01 Epub Date: 2024-10-22 DOI: 10.1080/17474124.2024.2419519

Bernardo Stefanini, Giulia F Manfredi, Antonio D'Alessio, Claudia A M Fulgenzi, Nichola Awosika, Ciro Celsa, Mario Pirisi, Cristina Rigamonti, Michela Burlone, Federica Vincenzi, Rosalba Minisini, Alessandra Gennari, Vincent Yip, Sarah Slater, Karim El-Shakankery, Ananya Jain, Francesco Tovoli, Fabio Piscaglia, Duncan Spalding, Madhava Pai, David J Pinato

{"title":"Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma.","authors":"Bernardo Stefanini, Giulia F Manfredi, Antonio D'Alessio, Claudia A M Fulgenzi, Nichola Awosika, Ciro Celsa, Mario Pirisi, Cristina Rigamonti, Michela Burlone, Federica Vincenzi, Rosalba Minisini, Alessandra Gennari, Vincent Yip, Sarah Slater, Karim El-Shakankery, Ananya Jain, Francesco Tovoli, Fabio Piscaglia, Duncan Spalding, Madhava Pai, David J Pinato","doi":"10.1080/17474124.2024.2419519","DOIUrl":"10.1080/17474124.2024.2419519","url":null,"abstract":"Introduction: Hepatocellular carcinoma (HCC) presents a formidable challenge in oncology, demanding innovative treatment approaches. Both adjuvant and neoadjuvant therapies, thanks to the introduction of immunotherapy, have emerged as promising strategies in the management of HCC, aiming to reduce the risk of relapse and ultimately to improve survival.Areas covered: This review considers current evidence, ongoing clinical trials, and future strategies to elucidate the evolving landscape of neoadjuvant and adjuvant treatments in HCC.Expert opinion: Both adjuvant and neoadjuvant regimens, notably those incorporating immune checkpoint inhibitors, demonstrated encouraging safety profiles and efficacy outcomes in HCC.While significant challenges persist, including optimizing patient selection and endpoint definition, the evolving landscape of neoadjuvant and adjuvant therapy holds promise for maximizing the therapeutic potential of immunotherapy across all stages of HCC. Further insights into tumor biology and host immunity will shape the role of these approaches which are close to becoming reality in clinical practice.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"647-660"},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolites derived from gut microbiota mitigate chemoresistance in pancreatic cancer. 来自肠道微生物群的代谢物可减轻胰腺癌的化疗耐药性。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-10-01 Epub Date: 2024-10-22 DOI: 10.1080/17474124.2024.2412045

Juan Deng, Dongmei Deng, Bing Wang, Valentina Donati, Adam E Frampton, Elisa Giovannetti

{"title":"Metabolites derived from gut microbiota mitigate chemoresistance in pancreatic cancer.","authors":"Juan Deng, Dongmei Deng, Bing Wang, Valentina Donati, Adam E Frampton, Elisa Giovannetti","doi":"10.1080/17474124.2024.2412045","DOIUrl":"10.1080/17474124.2024.2412045","url":null,"abstract":"Introduction: Pancreatic ductal adenocarcinoma (PDAC) is the third-leading cause of tumor-related deaths. The gut microbiota has gained attention in cancer treatment, due to its influence on the immune system and drug activity.Areas covered: Tintelnot and collaborators highlight distinct gut microbiota composition in metastatic PDAC (mPDAC) patients responding versus non-responding to chemotherapy. In the context of chemotherapy treatment, the gut microbiota of responders can metabolize tryptophan from food into indole-3-acetic acid (3-IAA). The presence of neutrophil-derived myeloperoxidase facilitates the role of 3-IAA in promoting the accumulation of reactive oxygen species in tumor cells. This accumulation, in turn, inducing tumor cell cytotoxicity. Additionally, 3-IAA can inhibit tumor cell autophagy activity, diminishing tumor cells' ability to adapt to cell stress. This manuscript provides a comprehensive analysis of the latest research on microbiota, metabolites, and PDAC, sourced from PubMed, ScienceDirect, and Google Scholar.Expert opinion: The evaluated study noted an elevation of the bacterial metabolite 3-IAA in responsive PDAC patients' serum, suggesting its potential to enhance chemotherapy sensitivity. Gaining a thorough comprehension of the impact of gut microbiota metabolites on drug activity is beneficial for broadening our strategies to mitigate chemotherapy resistance in tumors and identifying markers that predict chemotherapy outcomes.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"597-604"},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disconnected pancreatic duct syndrome: diagnostic and therapeutic challenges and future directions. 胰管断裂综合征：诊断和治疗的挑战与未来方向。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-10-01 Epub Date: 2024-10-24 DOI: 10.1080/17474124.2024.2419056

Mamoru Takenaka, Tomotaka Saito, Tsuyoshi Hamada, Shunsuke Omoto, Hideyuki Shiomi, Takuji Iwashita, Atsuhiro Masuda, Saburo Matsubara, Akinori Maruta, Keisuke Iwata, Tsuyoshi Mukai, Hiroyuki Isayama, Ichiro Yasuda, Yousuke Nakai

{"title":"Disconnected pancreatic duct syndrome: diagnostic and therapeutic challenges and future directions.","authors":"Mamoru Takenaka, Tomotaka Saito, Tsuyoshi Hamada, Shunsuke Omoto, Hideyuki Shiomi, Takuji Iwashita, Atsuhiro Masuda, Saburo Matsubara, Akinori Maruta, Keisuke Iwata, Tsuyoshi Mukai, Hiroyuki Isayama, Ichiro Yasuda, Yousuke Nakai","doi":"10.1080/17474124.2024.2419056","DOIUrl":"10.1080/17474124.2024.2419056","url":null,"abstract":"Introduction: Disconnected pancreatic duct syndrome (DPDS) is a pathological condition that causes various symptoms due to the continuous secretion of pancreatic enzymes from the pancreas upstream, which has been separated due to disconnection of the pancreatic duct (DPD) for various reasons.Acute necrotizing pancreatitis includes a certain probability of DPDS appearance, which makes it necessary to provide various treatments for DPDS. Furthermore, DPDS can impact long-term results, such as recurrence and impaired pancreatic function. Although the development of various modalities has contributed to diagnosis and treatment, especially less invasive endoscopic therapy, DPDS is often overlooked, and the diagnosis can be delayed due to the lack of consensus on its definition and classification. This review summarizes the current knowledge and challenges of DPDS and discusses the optimal strategy for its diagnosis and treatment, as well as future perspectives.Areas covered: Given the lack of established definition, diagnosis, and treatment of DPDS, we conducted a thorough review of the existing literature.Expert opinion: It is emphasized that a standardized definition and classification of DPDS is essential for designing and conducting clinical studies to address current unmet needs in managing patients with DPDS.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"631-645"},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of ulcerative colitis: where are we at and where are we heading? 溃疡性结肠炎的治疗：现状与未来？

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-10-01 Epub Date: 2024-11-07 DOI: 10.1080/17474124.2024.2422370

Adnan Abbas, David M P Di Fonzo, Panu Wetwittayakhlang, Reem Al-Jabri, Peter L Lakatos, Talat Bessissow

{"title":"Management of ulcerative colitis: where are we at and where are we heading?","authors":"Adnan Abbas, David M P Di Fonzo, Panu Wetwittayakhlang, Reem Al-Jabri, Peter L Lakatos, Talat Bessissow","doi":"10.1080/17474124.2024.2422370","DOIUrl":"10.1080/17474124.2024.2422370","url":null,"abstract":"Introduction: Remission rates for ulcerative colitis (UC) remain low despite significant progress in disease understanding and the introduction of novel therapeutic agents. Several challenges contribute to this, including the heterogeneity of the disease, suboptimal efficacy of current diagnostic and therapeutic tools, drug safety concerns, and limited access to newer treatment options.Areas covered: This review evaluates current treatment targets in UC, assessing the effectiveness of various therapies and management strategies in achieving remission. We explore the potential role of personalized medicine, which tailors treatment based on clinical predictors, genetic factors, and immunologic profiles. Personalized approaches show promise in improving remission rates by addressing the unique characteristics of each patient. We also discussed the feasibility of adapting such management models and suggested solutions to some of the challenges in their implementation.Expert opinion: Future efforts should prioritize the continued development of biologics, small molecules, and digital health solutions, alongside noninvasive monitoring techniques. These innovations could not only enhance patient outcomes by improving remission rates but also reduce healthcare costs by minimizing hospitalization and surgical interventions. Ultimately, a personalized, stratified approach to UC management is key to optimizing patient care and addressing the unmet needs in this field.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"567-574"},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of videocapsule endoscopy in the diagnosis and follow-up of celiac disease: a scoping review. 视频胶囊内镜在乳糜泻诊断和随访中的作用：范围综述。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-10-01 Epub Date: 2024-11-04 DOI: 10.1080/17474124.2024.2422372

Roberta Elisa Rossi, Valeria Poletti, Benedetta Masoni, Angelo Zullo, Matteo Colombo, Cesare Hassan, Alessandro Repici

{"title":"The role of videocapsule endoscopy in the diagnosis and follow-up of celiac disease: a scoping review.","authors":"Roberta Elisa Rossi, Valeria Poletti, Benedetta Masoni, Angelo Zullo, Matteo Colombo, Cesare Hassan, Alessandro Repici","doi":"10.1080/17474124.2024.2422372","DOIUrl":"10.1080/17474124.2024.2422372","url":null,"abstract":"Introduction: Videocapsule endoscopy (VCE) may be a complementary tool in the diagnosis of celiac disease (CD) in cases with equivocal findings and in the follow-up of complicated cases. We aimed to summarize the literature on the utilization of VCE in CD diagnosis/follow-up.Methods: A computerized literature search was performed to identify pertinent articles published between January 2010 and January 2024.Results: Three studies focused on VCE in diagnosing CD, involving a total of 186 patients. VCE was performed due to small bowel atrophy with negative serology (19 patients), positive serology with negative histology (40 patients), contraindications/refusal to undergo esophagogastroduodenoscopy (6 patients), high clinical suspicion of CD despite negative serology and/or small bowel atrophy (99 patients), research purpose (22 patients). Twenty studies focused on the follow-up, involving a total of 1337 patients. VCE was performed due to positive serology despite GFD (64 patients), persistent symptoms (389 patients), known/suspected refractory CD-RCD (448 patients), not specified (436 patients). VCE revealed RCD in 243 patients, ulcerative jejunoileitis in 32, T-cell lymphoma in 18, small bowel tumor in one.Conclusions: VCE may play a role in patients with equivocal CD diagnosis and in those with suspected complications, particularly RCD. Further studies are warranted to draw more solid conclusions.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"673-679"},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Principle of sample size calculation in gastroenterology research: a practical guide for clinicians. 胃肠病学研究样本量计算原则：临床医师实用指南》。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-10-01 Epub Date: 2024-10-16 DOI: 10.1080/17474124.2024.2416239

Antonio Facciorusso, Viktor Domislovic, Lorenzo Fuccio, Ivo Boskoski, Cristiano Spada, Gabriele Capurso, Marianna Arvanitakis, Marcello Maida

{"title":"Principle of sample size calculation in gastroenterology research: a practical guide for clinicians.","authors":"Antonio Facciorusso, Viktor Domislovic, Lorenzo Fuccio, Ivo Boskoski, Cristiano Spada, Gabriele Capurso, Marianna Arvanitakis, Marcello Maida","doi":"10.1080/17474124.2024.2416239","DOIUrl":"10.1080/17474124.2024.2416239","url":null,"abstract":"Introduction: A proper sample size calculation enables to conduct adequately powered randomized controlled trials (RCTs) and to provide a valid assessment of a specific clinical question.Areas covered: In the current manuscript, we tried to provide the reader with an easy guide on the principles of sample size calculation in RCTs, tailored specifically to the context of gastroenterology and hepatology. The basics of sample size calculation were commented with a description of some of the main methods, including the calculation of the non-inferiority margin for non-inferiority RCTs and the calculation of the minimum clinically important difference (MCID). Some examples from the gastroenterology literature were also provided.Expert opinion: Collaborating with a biostatistician can provide valuable insights into the nuances of sample size calculation and study design. However, it is crucial that the clinicians understand the basics of calculating sample size, so they could provide valuable input in designing the study from a clinical point of view.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"561-565"},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0